First Patient Dosed in EB103 Expansion Phase; Durable CRs Reported in Lymphoma Trial
ESLA is trading near its 52-week low of $0.73 (4.2% above the low) on light trading volume (0.2× avg).
Summary
Estrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 trial for EB103 in relapsed/refractory B-cell NHL. The company also reported that all evaluable Phase I patients who achieved complete response remained in CR at the 6-month assessment, signaling durable efficacy. This marks a concrete clinical advance for a micro-cap biotech trading near its 52-week low and facing going-concern risk. The expansion data will inform a pivotal trial strategy, a key value driver. With a market cap around $33M, positive early efficacy could attract partnership interest or improve financing prospects, though cash runway remains a critical concern.
At the time of this announcement, ESLA was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.9M. The 52-week trading range was $0.73 to $3.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.